Evidence map›Paper›PMID 25744878›Full record

ArticleEuropean journal of pharmacology2015

Reprint of: Highthroughtput analysis of behavior for drug discovery.

Vadim Alexandrov, Dani Brunner, Taleen Hanania, Emer Leahy

Open access · hybridAbstract readDuplicate Publication
PubMed Publisher
In one paragraph

Article in European journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vadim AlexandrovPsychoGenics Inc., Tarrytown, New York, USA.
Dani BrunnerPsychoGenics Inc., Tarrytown, New York, USA. Electronic address: info@psychogenics.com.
Taleen HananiaPsychoGenics Inc., Tarrytown, New York, USA.
Emer LeahyPsychoGenics Inc., Tarrytown, New York, USA.
Psychogenics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed three comprehensive highthroughtput systems, SmartCube(®), NeuroCube(®) and PhenoCube(®) systems, to increase the efficiency of the drug screening and phenotyping in rodents. These three systems capture different domains of behavior, namely, cognitive, motor, circadian, social, anxiety-like, gait and others, using custom-built computer vision software and machine learning algorithms for analysis. This review exemplifies the use of the three systems and explains how they can advance drug screening with their applications to phenotyping of disease models, drug screening, selection of lead candidates, behavior-driven lead optimization, and drug repurposing.

Indexed as

Behavioral screeningCNS diseasesComputer vision softwareDisease modelsDrug discoveryDrug screeningHigh-throughputMachine learning algorithmsNeuroCube, PhenoCubePhenotypingPreclinical researchSmartCubeSocial behavior, animal models

Identifiers

PMID25744878
OpenAlexW2037932359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.